12:00 AM
 | 
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Egrifta tesamorelin: Phase II data

A double-blind, U.S. Phase II trial in 60 obese patients with moderate growth hormone deficiency showed that once-daily 2 mg subcutaneous tesamorelin significantly reduced visceral fat by 19%, cIMT by 6% and triglycerides by 20% at 1 year vs. placebo. Tesamorelin produced no significant effects on abdominal subcutaneous adipose tissue, fasting glucose, 2-hour glucose or HbA1c levels. Tesamorelin did...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >